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ABSTRACT
ObjeCtive
To critically evaluate the efficacy of renin angiotensin 
system inhibitors (RASi) in patients with coronary 
artery disease without heart failure, compared with 
active controls or placebo.
Design
Meta-analysis of randomized trials.
Data sOurCes
PubMed, EMBASE, and CENTRAL databases until  
1 May 2016.
eligibility Criteria fOr seleCting stuDies
Randomized trials of RASi versus placebo or active 
controls in patients with stable coronary artery disease 
without heart failure (defined as left ventricular 
ejection fraction ≥40% or without clinical heart 
failure). Each trial had to enroll at least 100 patients 
with coronary artery disease without heart failure, with 
at least one year’s follow-up. Studies were excluded if 
they were redacted or compared use of angiotensin 
converting enzyme inhibitors with angiotensin 
receptor blockers. Outcomes were death, 
cardiovascular death, myocardial infarction, angina, 
stroke, heart failure, revascularization, incident 
diabetes, and drug withdrawal due to adverse effects.
results
24 trials with 198 275 patient years of follow-up were 
included. RASi reduced the risk of all cause mortality 
(rate ratio 0.84, 95% confidence interval 0.72 to 0.98), 
cardiovascular mortality (0.74, 0.59 to 0.94), 
myocardial infarction (0.82, 0.76 to 0.88), stroke 
(0.79, 0.70 to 0.89), angina, heart failure, and 
revascularization when compared with placebo but not 
when compared with active controls (all cause 
mortality, 1.05, 0.94 to 1.17; Pinteraction=0.006; 
cardiovascular mortality, 1.08, 0.93 to 1.25, 
Pinteraction<0.001; myocardial infarction, 0.99, 0.87 to 
1.12, Pinteraction=0.01; stroke, 1.10, 0.93 to 1.31; 
Pinteraction=0.002). Bayesian meta-regression analysis 
showed that the effect of RASi when compared with 
placebo on all cause mortality and cardiovascular 
mortality was dependent on the control event rate, 
such that RASi was only beneficial in trials with high 
control event rates (>14.10 deaths and >7.65 
cardiovascular deaths per 1000 patient years) but not 
in those with low control event rates.
COnClusiOns
In patients with stable coronary artery disease without 
heart failure, RASi reduced cardiovascular events and 
death only when compared with placebo but not when 
compared with active controls. Even among placebo 
controlled trials in this study, the benefit of RASi was 
mainly seen in trials with higher control event rates but 
not in those with lower control event rates. Evidence 
does not support a preferred status of RASi over other 
active controls.
Introduction
Renin angiotensin system inhibitors (RASi) have been 
documented to reduce the risk of cardiovascular events 
and overall mortality when compared with placebo in 
patients with coronary artery disease and even in those 
without apparent heart failure.1 2  Because the mean sys-
tolic blood pressure on entry in these trials was lower 
than 140 mm Hg and the end of trial difference in blood 
pressure between the two treatment strategy was mini-
mal, the favorable effect of RASi on outcomes has been 
dubbed as a “blood pressure independent effect”—a 
vasculoprotective properties of these drugs.3
However, in the Prevention of Events with Angioten-
sin Converting Enzyme Inhibition (PEACE) trial of 
patients with stable coronary artery disease and normal 
or slightly reduced left ventricular function, RASi pro-
vided no further benefit when compared with placebo.4 
Similar results with no benefit of RASi were seen in the 
Quinapril Ischemic Event Trial (QUIET)5 , Comparison 
of Amlodipine vs Enalapril to Limit Occurrences of 
Thrombosis (CAMELOT) study,6  and Ischemia Manage-
ment With Accupril Post-Bypass Graft via Inhibition of 
the Converting Enzyme (IMAGINE) trial.7  These seem-
ingly incongruous findings were attributed to lower rate 
of events in these four trials than in the HOPE and 
EUROPA trials,1 2 owing to increased use of intense 
treatment including revascularization and lipid lower-
ing treatment.
WhAT IS AlReAdy knoWn on ThIS TopIC
Renin angiotensin system inhibitors (RASi) are strongly recommended by 
guidelines (class I or IIa) for patients with coronary artery disease without heart 
failure, on the basis of early studies of RASi versus placebo showing significant 
reduction in cardiovascular events including mortality
However, later studies with improvement in background treatment showed no 
benefit of RASi versus placebo
WhAT ThIS STudy AddS
In patients with stable coronary artery disease without heart failure, a significant 
benefit of RASi was seen for the reduction of cardiovascular events and all cause 
mortality only in comparison with placebo but not with active controls
Even among the placebo controlled trials, the benefits were only seen in trials with 
high baseline risk and not in those with low baseline risk
The blanket recommendation to use RASi for all patients with coronary artery 
disease is not supported by evidence
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Despite the above, the American College of Cardiology 
Foundation (ACCF)/American Heart Association (AHA) 
guidelines on stable ischemic heart disease recom-
mends RASi in patients who also have hypertension, 
diabetes, left ventricular ejection fraction (LVEF) of 40% 
or less, or chronic kidney disease, unless contraindi-
cated (class I, level A) or in patients with other vascular 
disease (class IIa).8 The objective of the current study 
was to critically evaluate the efficacy of RASi in patients 
with coronary artery disease without heart failure.
Methods
Database search and eligibility criteria
We searched PubMed, Cochrane Central Register of 
Controlled Trials (CENTRAL), and EMBASE until 1 May 
2016, for randomized controlled trials of RASi (angio-
tensin converting enzyme inhibitors or angiotensin 
receptor blockers) in patients with coronary artery dis-
ease without heart failure. The MeSH terms used are 
outlined in table S1. There was no language restriction 
for the search. In addition, we searched the bibliogra-
phies of original trials, meta-analyses, and review arti-
cles identified to find other eligible trials, and kept up to 
date with the search by weekly reminders from PubMed.
Eligible trials had to fulfill the following criteria: 
compared RASi with placebo or active controls; enrolled 
at least 100 patients with coronary artery disease with-
out heart failure (defined as LVEF ≥40% or without clin-
ical heart failure) with follow-up of at least one year (to 
minimize small study effect); and reported the out-
comes of interest (see below). We excluded studies if 
they were redacted for any reason or compared use of 
angiotensin converting enzyme inhibitors with angio-
tensin receptor blockers. Given that there was no 
patient recruitment, ethical approval was not required.
Data extraction and bias assessment
Three authors (RF, BT, SB) independently assessed trial 
eligibility and trial bias risk and extracted data. Disagree-
ments were resolved by consensus. The trials’ bias risk 
was assessed with the components recommended by the 
Cochrane Collaboration for randomized trials.9 These 
components include allocation sequence generation, 
allocation concealment, blinding of outcome assessors, 
incomplete outcome data, and selective outcome report-
ing. For each component, trials were categorized as low, 
high, or unclear risk of bias. The trials did not differ by 
the last two components, and thus we considered trials 
with high or unclear risk for bias for the first three com-
ponents to represent trials with high risk of bias.
Outcomes
Primary outcomes evaluated were all cause mortality, 
cardiovascular death, myocardial infarction, stroke, 
angina pectoris, and heart failure. Secondary outcomes 
evaluated were revascularization, incident diabetes, 
and drug withdrawal due to adverse effects.
statistical analyses
Trial level meta-analysis was performed as per the rec-
ommendations from the Cochrane Collaboration and 
the preferred reporting items for systematic reviews and 
meta-analyses (PRISMA) statement.9 10 We performed 
the analysis using an intention to treat approach. Anal-
yses compared RASi versus placebo and RASi versus 
active controls separately. A test for interaction was 
used to compare the quantitative (magnitude) and qual-
itative direction of the effect size for the placebo and 
active control trials, with Pinteraction<0.05 considered sta-
tistically significant.
We calculated the meta-analytic summary estimates 
(rate ratio) using the fixed effect model and the random 
effects model of DerSimonian and Laird.11  Continuity 
correction was used for trials with zero events to enable 
finite variance estimators to be derived.12 Heterogeneity 
(proportion of total variation observed between the tri-
als attributable to differences between trials rather than 
chance) was assessed using the I2 statistic13 (<25%=low; 
>75%=high). We assessed small study effect using the 
Begg’s and the Egger’s test and by visual evaluation of 
the funnel plots for asymmetry.
Heterogeneity of treatment effect
For the heterogeneity of treatment effect based on base-
line risk, we calculated the event rate per 1000 patient 
years of follow-up in the control arm (placebo or active) 
of the trial. The control event rate is a good measure of 
not only the baseline clinical characteristic of the 
enrolled cohort (such as the proportion with diabetes or 
kidney disease), but also the background treatment 
(such as statin use). Conventional meta-regression of 
the treatment effect with the control event rate as 
explanatory variable is problematic because it ignores 
the correlation between the treatment effect and the 
control event rate. Therefore, a Bayesian meta-regres-
sion was used, which accounts appropriately for this 
correlation.14 15
A strong interaction effect between the treatment 
effect and the baseline risk is indicated if the 95% cred-
ible interval for the control event rate parameter 
excludes zero. To further quantify this interaction, a 
credible band for the relation between the treatment 
effect and baseline risk was calculated, and the turning 
point for which there is no treatment effect (that is, rate 
ratio=1) was calculated. Vague priors were used for all 
parameters; we conducted all analyses using WinBUGS 
1.4.3 and R 3.3.0.
We did a conventional meta-regression analysis to 
evaluate the relation of the following potential effect 
modifiers to the risk of outcomes with RASi: end of trial 
systolic blood pressure difference between treatment 
arms, percentage of patients with hypertension, per-
centage of patients with diabetes, and percentage of 
patients on statins. This was done separately for pla-
cebo controlled trials versus active controlled trials. We 
used a residual maximum likelihood to estimate the 
additive (between study) component of variance τ2 for 
the meta-regression analysis. Bootstrap analyses were 
performed with a Monte Carlo permutation test for 
meta-regression using 10 000 random permutations.16 
We used standard statistical software (Stata 12.1, Stata) 
to conduct analyses.17
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Sensitivity analysis
Sensitivity analyses were performed for the following 
subgroups: trials with mean baseline systolic blood 
pressure 140 mm Hg or less versus more than 140 mm 
Hg (to evaluate whether the benefit of RASi is restricted 
to patients with higher entry blood pressure); trials 
enrolling patients with recent myocardial infarction 
(defined as ≤3 months) versus those not (to evaluate 
whether the benefit of RASi is restricted to patients 
with recent myocardial infarction); and trials using 
angiotensin converting enzyme inhibitors compared 
with those using angiotensin receptor blockers as the 
treatment.
Trial sequential analysis
To compare RASi with active controls, the lack of signif-
icant benefit of RASi could merely be due to type II 
error. To evaluate this, we used trial sequential analysis 
to evaluate whether the RASi versus active controls 
comparisons had adequate power. For trial sequential 
analysis, monitoring boundaries are drawn for each 
outcome, similar to interim analysis of randomized tri-
als. This provides information on whether to continue 
evaluating for evidence when the boundary is not 
crossed or whether sufficient evidence is reached for 
anticipated effect or for futility when the boundary is 
crossed. Trial sequential analysis was performed by 
estimation of the required diversity adjusted informa-
tion size (sample size),18  anticipating a 15-20% relative 
risk reduction for the outcome (death, cardiovascular 
death, stroke), α=5% and 1−β=90%. The methodology 
has been described previously.19 20 The 15-20% relative 
reduction was chosen because it is the nominal effect 
size seen in cardiovascular trials that is both clinically 
meaningful and realistic.
Patient involvement
No patients were involved in setting the research ques-
tion or the outcome measures, nor were they involved in 
developing plans for design or implementation of the 
study. No patients were asked to advise on interpreta-
tion or writing up of results. There are no plans to dis-
seminate the results of the research to study participants 
or the relevant patient community.
Results
study selection
Our search included 24 trials that satisfied the inclu-
sion and exclusion criteria (fig S1). The trials enrolled 
61 961 patients who were followed up for an average of 
3.2 years, for a total of 198 275 patient years of fol-
low-up (tables S2-S3). Of the included trials, five 
enrolled patients within three months of acute myo-
cardial infarction, 18 were placebo controlled, and 
seven were active controlled. The active comparison 
groups were calcium antagonists (four trials), thiazide 
diuretic (one), and conventional treatment (two). 
Nineteen trials had mean systolic blood pressure 
lower than 140 mm Hg at baseline. The baseline char-
acteristics and bias risk assessment of the trials are 
outlined in tables S2-S3.
all cause mortality
RASi reduced the risk of all cause mortality when com-
pared with placebo (rate ratio 0.84, 95% confidence 
interval 0.72 to 0.98) but not when compared with active 
controls (1.05, 0.94 to 1.17; Pinteraction=0.006; fig 1 ). Bayes-
ian meta-regression showed that the beneficial effect of 
RASi versus placebo on all cause mortality depended on 
the control event rate, such that RASi was only benefi-
cial in trials with a high control event rate (>14.10 
deaths per 1000 patient years) but not in those with a 
low control event rate (fig 2 ). The other effect modifiers 
were not significant predictors (tables S8-S9). Trial 
sequential analysis for RASi versus active controls 
showed that the cumulative Z curve did not cross either 
the conventional boundary or the trial sequential mon-
itoring boundary, indicating lack of even a 15% benefit 
of RASi over active controls with 90% power (fig S3). 
There was moderate statistical heterogeneity in the 
comparison versus placebo but no statistical heteroge-
neity in the comparison with active controls (fig 1).
Cardiovascular mortality
RASi reduced the risk of cardiovascular mortality when 
compared with placebo (rate ratio 0.74, 95% confidence 
interval 0.59 to 0.94) but not when compared with active 
controls (1.08, 0.93 to 1.25; Pinteraction<0.001; fig 3 ). Bayes-
ian meta-regression showed that the beneficial effect of 
RASi versus placebo on cardiovascular mortality 
depended on the control event rate such that RASi was 
only beneficial in trials with a high control event rate 
(>7.65 cardiovascular deaths per 1000 patient years) but 
not in those with a low control event rate (fig 4 ). The other 
effect modifiers were not significant predictors (tables 
S8-S9). Trial sequential analysis for RASi versus active 
controls showed that the cumulative Z curve did not cross 
either the conventional boundary or the trial sequential 
monitoring boundary, indicating lack of even a 15% ben-
efit of RASi over active controls with 90% power (fig S4). 
There was moderate statistical  heterogeneity in the com-
parison of RASi versus placebo, but no statistical hetero-
geneity in the comparison with active controls (fig 4).
Myocardial infarction
RASi reduced the risk of myocardial infarction when 
compared with placebo (rate ratio 0.82, 95% confidence 
interval 0.76 to 0.88) but not when compared with active 
controls (0.99, 0.87 to 1.12; Pinteraction=0.01; fig 5 ). Bayes-
ian meta-regression showed that the beneficial effect of 
RASi versus placebo on myocardial infarction depended 
on the control event rate such that RASi was beneficial 
in trials with a high control event rate but not in those 
with a low control event rate (fig 6 ). However, the 95% 
credibility for β included zero (−0.38 to 0.15). Moreover, 
the end of trial systolic blood pressure difference 
between RASi and placebo explained 93.1% of the 
between study variance—that is, RASi was beneficial 
when compared with placebo mainly in trials with a 
greater difference in systolic blood pressure at the end 
of the trial (fig S3). Trial sequential analysis for RASi 
versus active controls showed that the cumulative Z 
curve did not cross either the conventional boundary or 
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the trial sequential monitoring boundary, indicating 
lack of even a 20% benefit of RASi over active controls 
with 90% power (fig S5). There was no statistical hetero-
geneity in the analysis (fig 5).
stroke
RASi reduced the risk of stroke when compared with 
placebo (rate ratio 0.79, 95% confidence interval 0.70 
to 0.89) but not when compared with active controls 
(1.10, 0.93 to 1.31; Pinteraction=0.002; fig 7 ). Bayesian 
meta-regression showed that the beneficial effect of 
RASi versus placebo on stroke depended on the con-
trol event rate such that RASi was beneficial in trials 
with a high control event rate but not in those with a 
low control event rate. However, the 95% credibility 
for β included zero (−0.69 to 0.06). The other effect 
modifiers were not significant predictors (tables 
S8-S9). There was no or low statistical heterogeneity 
in the analysis (fig 7).
angina
RASi reduced the risk of angina when compared with 
placebo (rate ratio 0.94, 95% confidence interval 0.89 to 
0.99) but not when compared with active controls (1.07, 
0.85 to 1.35; Pinteraction=0.03; fig 8 ). The other effect mod-
ifiers were not significant predictors (tables S8-S9). 
There was low statistical heterogeneity in the 
Control event rate per 1000 patient years (λc)
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fig 2 | bayesian meta-regression analysis of the influence 
of baseline risk (control event rate) on the effect size of 
rasi versus placebo on all cause mortality
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fig 1 | forest plot showing 
effect of renin angiotensin 
system inhibitors (rasi) 
versus placebo or active 
controls on all cause 
mortality in patients with 
stable coronary artery 
disease without heart 
failure. D+l=Dersimonian 
and laird; i-v=inverse 
variance; CHD=coronary 
heart disease 
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 comparison versus placebo but moderate statistical 
heterogeneity in the comparison with active controls 
(fig 8).
Heart failure
RASi reduced the risk of heart failure when compared 
with placebo (rate ratio 0.78, 95% confidence interval 
0.71 to 0.86) but not when compared with active con-
trols (0.89, 0.62 to 1.29; Pinteraction=0.49; fig 9 ). The other 
effect modifiers were not significant predictors (tables 
S8-S9). There was moderate statistical heterogeneity in 
the comparison versus placebo but no statistical hetero-
geneity in the comparison with active controls (fig 9).
revascularization, incident diabetes, and drug 
withdrawal due to adverse effects
RASi reduced the risk of revascularization when com-
pared with placebo (rate ratio 0.93, 95% confidence 
interval 0.89 to 0.98) but not when compared with 
active controls (1.02, 0.94 to 1.12; Pinteraction=0.07; fig S6). 
The other effect modifiers were not significant predic-
tors (tables S8-S9). There was low statistical heteroge-
neity in the analysis (fig S6). RASi also reduced the risk 
of incident diabetes when compared with placebo 
(0.84, 0.76 to 0.92) and with active controls (0.39, 0.16 to 
0.93; Pinteraction=0.09; fig S7). There was moderate statis-
tical heterogeneity in the analysis (fig S7). When 
Placebo
  APRES
  CAMELOT
  Cai et al
  EUROPA
  HOPE
  IMAGINE
  JAMP
  Kondo et al
  PART-2
  PEACE
  PRACTICAL
  QUIET
  QUO VADIS
  ROADMAP (CHD subgroup)
  SCAT
  TRANSCEND
D+L subtotal: P=0, I2=73.2%
I-V subtotal
Active
  ALLHAT (CHD subgroup)
  CAMELOT
  CARP
  HIJ-CREATE
  JMIC-B
  NAGOYA HEART (CHD subgroup)
  OLIVUS
D+L subtotal: P=0.853, I2=0%
I-V subtotal
D+L overall: P=0, I2=68.2%
I-V overall
Pinteraction (placebo v active)= 0.0008
0.14 (0.02 to 1.15)
2.43 (0.47 to 12.54)
0.32 (0.22 to 0.45)
0.86 (0.72 to 1.04)
0.75 (0.64 to 0.87)
1.19 (0.60 to 2.37)
0.87 (0.39 to 1.91)
0.22 (0.05 to 1.03)
0.45 (0.19 to 1.03)
0.96 (0.76 to 1.20)
0.38 (0.16 to 0.89)
0.92 (0.42 to 2.01)
0.97 (0.02 to 49.05)
10.53 (1.36 to 81.58)
0.58 (0.17 to 1.97)
1.02 (0.85 to 1.23)
0.74 (0.59 to 0.94)
0.81 (0.75 to 0.89)
1.09 (0.93 to 1.28)
0.99 (0.29 to 3.40)
1.12 (0.02 to 56.56)
1.12 (0.65 to 1.92)
1.01 (0.33 to 3.12)
0.12 (0.01 to 2.27)
0.48 (0.04 to 5.30)
1.08 (0.93 to 1.25)
1.08 (0.93 to 1.25)
0.80 (0.66 to 0.97)
0.87 (0.81 to 0.94)
0.78
1.22
8.40
10.75
11.05
4.72
3.94
1.38
3.66
10.2
3.47
3.97
0.23
0.81
2.02
10.72
77.32
11.01
1.99
0.23
6.12
2.31
0.41
0.60
22.68
100.00
0.01 0.1 1 10 100
Trials
Favors
RASi
Favors
control
Rate ratio
(95% CI)
Rate ratio
(95% CI)
Weight
(%)
1/80
5/673
43/478
215/6110
282/4645
18/1280
11/422
2/203
8/308
146/4158
9/150
12/878
0/75
11/564
4/229
227/2954
215/2270
5/673
0/90
28/1024
6/822
0/158
1/126
RASi
7/79
2/655
99/344
249/6108
377/4652
15/1273
14/466
9/203
18/309
152/4132
12/75
27/872
0/73
1/540
7/231
223/2972
534/6145
5/663
0/101
25/1025
6/828
4/174
2/121
Control
No of events/total
fig 3 | forest plot showing 
effect of renin angiotensin 
system inhibitors (rasi) 
versus placebo or active 
controls on cardiovascular 
mortality in patients with 
stable coronary artery 
disease without heart 
failure. D+l=Dersimonian 
and laird; i-v=inverse 
variance; CHD=coronary 
heart disease
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 compared with controls, there was a significant 
increase in the risk of drug withdrawal due to adverse 
effects with angiotensin converting enzyme inhibitors 
(1.57, 1.25 to 1.99) but not with angiotensin receptor 
blockers (0.66, 0.34 to 1.28; Pinteraction<0.001; fig S8; table 
S4). There was high statistical heterogeneity in the anal-
ysis (fig S8). 
There was no significant small study effect in all the 
analyses.
sensitivity analysis
For placebo controlled trials, the beneficial effect of 
RASi was independent of systolic blood pressure at 
baseline (Pinteraction>0.05; table S5). The benefit of RASi 
over placebo was seen both in trials that enrolled 
patients with recent myocardial infarction as well as 
those that enrolled patients with stable ischemic heart 
disease (Pinteraction>0.05; table S5). However, for the 
 outcomes of death (Pinteraction=0.004) and cardiovascular 
death (Pinteraction<0.001), the benefit was greater in 
patients with recent myocardial infarction than in those 
with stable ischemic heart disease (table S5).
For active control trials, there was a lack of benefit of 
RASi regardless of systolic blood pressure at baseline 
(Pinteraction>0.05; table S6). Of note, none of the trials 
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comparing RASi versus active controls enrolled patients 
with recent myocardial infarction. There was no statis-
tically significant difference between angiotensin con-
verting enzyme inhibitors versus active controls or 
angiotensin receptor blockers versus active controls for 
any of the efficacy outcomes (table S7). Angiotensin 
converting enzyme inhibitors were associated with an 
increase in angina when compared with active controls 
but only in the fixed effect model, not in the random 
effects model (table S7).
discussion
This analysis of patients with stable coronary artery dis-
ease and without heart failure included data from 
198 275 patient years of follow-up from randomized tri-
als. Although RASi reduced the risk of cardiovascular 
events (including all cause mortality) when compared 
with placebo, no such benefit was seen when compared 
with active controls. Moreover, even among the RASi 
versus placebo trials, the beneficial effect of RASi was 
restricted to trials with higher baseline risk but not in 
those with lower baseline risk.
rasi for patients with stable coronary artery 
disease without heart failure
In 2000, the landmark HOPE trial showed an impressive 
22% reduction in the primary composite outcome, and 
reductions in death (16%), cardiovascular death (26%), 
myocardial infarction (20%), stroke (32%), and heart 
failure (23%) with RASi (ramipril) when compared with 
placebo in 9297 high risk patients.1  Three years later, 
the EUROPA trial showed a similar benefit with RASi 
(perindopril), with a 20% reduction in the primary com-
posite endpoint and 22% reduction in myocardial 
infarction when compared with placebo in 12 218 
patients with stable coronary artery disease and no 
apparent heart failure.2
However, other trials subsequently failed to show a 
similar benefit. In the PEACE trial (2004) of 4158 
patients with stable coronary artery disease and normal 
or slightly reduced left ventricular function, RASi (per-
indopril) was no better than placebo at reducing cardio-
vascular events.4  Similarly, in the QUIET trial (2001) of 
patients after coronary angioplasty but without systolic 
left ventricular dysfunction, no benefit of RASi 
(quinapril) was seen when compared with placebo.5  In 
CAMELOT, the calcium antagonist amlodipine reduced 
adverse cardiovascular events in patients with coronary 
artery disease and normal blood pressure, whereas 
RASi (enalapril), despite a similar blood pressure 
reduction, was no better than placebo.6  Finally, no ben-
efit with RASi (quinapril) over placebo was seen in the 
IMAGINE trial (2008) of patients after bypass graft 
 surgery.7
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The lack of benefit in later trials could be due to 
lower event rate in these trials than those in the HOPE/
EUROPA trials, owing to increased use of revascular-
ization and lipid lowering treatment. However, the 
2012 ACCF/AHA guidelines continue to give a class I 
recommendations for RASi use in patients with stable 
coronary artery disease regardless of revascularization 
status or lipid lowering treatment therapy use in 
patients who also have hypertension, diabetes, LVEF 
of 40% or less, or chronic kidney disease and a class 
IIa recommendation for those with stable coronary 
artery disease and other vascular disease. We there-
fore explored the question as to the strength of the evi-
dence to support RASi use in patients with coronary 
artery disease without heart failure. In addition, given 
the availability of other agents such as diuretics, β 
blockers and calcium channel blockers, we specifi-
cally explored RASi use compared with active controls.
Our analysis with data from about 200 000 patient 
years of follow-up offers some insights: 
•	 RASi reduced the risk of cardiovascular events and all 
cause mortality when compared with placebo, similar 
to the results seen in HOPE and EUROPA. However, 
even in the placebo controlled trials, Bayesian 
meta-regression analysis showed that the baseline 
risk (as measured by control event rate) explained the 
heterogeneity of treatment effect such that RASi was 
only beneficial in trials with a higher baseline risk and 
not those with a lower baseline risk. Our results are 
consistent with the negative trials such as the QUIET, 
PEACE, CAMELOT, and IMAGINE trials.4-7 Thus the 
universal endorsement of RASi for all patients with 
stable coronary artery disease is not supported by 
even placebo controlled trials, and might apply only 
to patients with higher baseline risk. 
•	 RASi did not reduce the risk of cardiovascular events 
or mortality when compared with active controls. 
With 14 220 patients and 45 504 patient years of fol-
low-up, the trial sequential analysis showed that the 
lack of superiority of RASi over active controls was 
not due to trials being underpowered, because the 
analyses (for mortality, cardiovascular mortality, and 
myocardial infarction) had more than 90% power to 
show a 15-20% reduction in endpoints with RASi.
•	 Results were consistent between trials of angiotensin 
converting enzyme inhibitors and those of angiotensin 
receptor blockers when compared with active controls.
•	 There was no outcome for which a higher percentage 
of participants with either enrolled hypertension or 
diabetes conferred a statistically significant advan-
tage of RASi over active controls.
•	 RASi showed a consistent reduction in incident diabe-
tes when compared with placebo or active controls. 
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Other meta-analysis in patients with hypertension have 
shown that RASi reduces the risk of new onset diabetes 
compared with other antihypertensive drugs.21
•	 Among RASi, angiotensin converting enzyme inhibi-
tors had a higher withdrawal rate due to adverse 
events than controls, whereas angiotensin receptor 
blockers did not.
The lack of advantage of RASi over active controls for 
cardiovascular events could be due to three reasons. 
Firstly, the active controls are as good as RASi, and the 
effect is mediated mainly by a reduction in blood pres-
sure. Secondly, the enrolled cohort (unlike patients 
with heart failure or renovascular hypertension) might 
not have had an activated renin-angiotensin-aldoste-
rone system, resulting in less benefit. And finally, in this 
cohort, the renin-angiotensin-aldosterone system could 
have had a role in delaying the chronic process of ath-
erogenesis and the benefit might not have been appar-
ent during the short follow-up in these trials. 
Therefore, our findings have important implications 
for clinical practice; they do not support the broad use 
of RASi for all patients with stable ischemic heart 
 disease as has been recommended by current guide-
lines. The class I recommendation for patients with 
 stable coronary artery disease and either diabetes or 
hypertension is not fully supported by the data in that 
the outcomes were similar to active comparators. Even 
among placebo controlled trials, RASi was no better 
than placebo in trials with lower baseline risk. This lack 
of benefit could have implications for patients with sta-
ble coronary artery disease with aggressive manage-
ment of risk factors such as hypertension and 
hypercholesterolemia (with high intensity statins) and 
consequent lower baseline residual risk. 
However, the current study did not evaluate other 
class I indications for RASi such as in patients with 
LVEF of 40% or less (where there is evidence of signifi-
cant benefit of RASi) or in those with chronic kidney 
disease. Similarly, the class IIa recommendation for 
patients with stable coronary artery disease and other 
vascular diseases is also not fully supported by the data 
in that the outcomes were similar to active comparators. 
This begs the question as to the evidence to support the 
preferential recommendation for RASi for this indica-
tion. Similar results were seen in an analysis from the 
Reduction of Atherothrombosis for Continued Health 
(REACH) registry, where the use of angiotensin 
 converting enzyme inhibitors or angiotensin receptor 
blockers was not associated with better outcomes in 
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fig 9 | forest plot showing effect of renin angiotensin system inhibitors (rasi) versus placebo or active controls on heart 
failure in patients with stable coronary artery disease without heart failure on trial entry
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20 909 outpatients with stable coronary artery disease 
and free of clinical heart failure at baseline.22
study limitations
This meta-analysis had trial level data and hence we 
were unable to control for between trial differences. Not 
all trials had data on ejection fraction for all patients. 
Although many trials included patients based on an 
ejection fraction threshold, others based their inclusion 
on absence of clinical heart failure or an ejection frac-
tion threshold. These results do not apply to cohorts not 
included in the present study, such as those with heart 
failure and chronic kidney disease. Not all of the trials 
reported each of the outcomes tested. Moreover, the 
active comparators were mainly calcium antagonists, 
and the results should not be extrapolated to other 
drugs not tested in the included trials.
Conclusions
In patients with stable coronary artery disease without 
heart failure, the current body of evidence from ran-
domized trials shows a significant benefit of RASi for 
the reduction of cardiovascular events and all cause 
mortality only in comparison with placebo but not with 
active controls. Moreover, even among the placebo con-
trolled trials, the benefit of RASi was only seen in trials 
with high baseline risk and not in those with low base-
line risk. Therefore, the blanket recommendation to use 
RASi for all patients with coronary artery disease is not 
supported by evidence.
Contributors: SB was responsible for the study concept and design, 
and supervised the study. RF, BT, and SB were responsible for 
acquisition of data. SB, RF, BT, and FHM were responsible for analysis 
and interpretation of data. SB drafted the manuscript, and SB, RF, BT, 
and FHM undertook for critical revision of the manuscript for important 
intellectual content. SB, SW, and JW did the statistical analysis. SB is the 
study guarantor, had full access to all of the trial level data in the study, 
takes responsibility for the integrity of the data, and accuracy of the 
data analysis, and had the final responsibility to submit for publication.
Funding: This work was not funded and hence there was no role of 
any funding source in the conception, data synthesis, analysis, 
interpretation, or in drafting of the manuscript.
Competing interests: All authors have completed the ICMJE uniform 
disclosure form at www.icmje.org/coi_disclosure.pdf and declare: no 
support from any organisation for the submitted work; SB declares 
honorariums from Daiichi-Sankyo, Pfizer, Abbott, Merck, Boerhinger-
Ingelheim, Gilead, and Abbott-Vascular; SW is employed and hold 
shares at Novartis Pharma AG (Basel, Switzerland); FHM declares 
honorariums from Daiichi-Sankyo, Pfizer, Abbott, Servier, WebMD, 
Ipca, American College of Cardiology, Menarini, and Relypsa; the 
remaining authors have no relevant disclosures; none of the authors 
received any compensation for their work on this manuscript.
Ethical approval: Not required.
Data sharing: No additional data available.
The lead author affirms that the manuscript is an honest, accurate, and 
transparent account of the study being reported; that no important 
aspects of the study have been omitted; and that any discrepancies from 
the study as planned (and, if relevant, registered) have been explained.
This is an Open Access article distributed in accordance with the 
Creative Commons Attribution Non Commercial (CC BY-NC 3.0) license, 
which permits others to distribute, remix, adapt, build upon this work 
non-commercially, and license their derivative works on different terms, 
provided the original work is properly cited and the use is non-
commercial. See: http://creativecommons.org/licenses/by-nc/3.0/.
1 Yusuf S, Sleight P, Pogue J, Bosch J, Davies R, Dagenais G. The 
Heart Outcomes Prevention Evaluation Study Investigators. Effects 
of an angiotensin-converting-enzyme inhibitor, ramipril, on 
cardiovascular events in high-risk patients. N Engl J Med 
2000;342:145-53. doi:10.1056/NEJM200001203420301. 
2 Fox KM. EURopean trial On reduction of cardiac events with 
Perindopril in stable coronary Artery disease Investigators. Efficacy of 
perindopril in reduction of cardiovascular events among patients with 
stable coronary artery disease: randomised, double-blind, 
placebo-controlled, multicentre trial (the EUROPA study). Lancet 
2003;362:782-8. doi:10.1016/S0140-6736(03)14286-9. 
3 Yusuf S, Lonn E.Anti-ischaemic effects of ACE inhibitors: review of 
current clinical evidence and ongoing clinical trials. Eur Heart J 
1998;19 (Suppl J):J36-44.
4 Braunwald E, Domanski MJ, Fowler SE, et al. PEACE Trial Investigators. 
Angiotensin-converting-enzyme inhibition in stable coronary artery 
disease. N Engl J Med 2004;351:2058-68. doi:10.1056/NEJMoa042739. 
5 Pitt B, O’Neill B, Feldman R, et al. QUIET Study Group. The QUinapril 
Ischemic Event Trial (QUIET): evaluation of chronic ACE inhibitor 
therapy in patients with ischemic heart disease and preserved left 
ventricular function. Am J Cardiol 2001;87:1058-63.  doi:10.1016/
S0002-9149(01)01461-8. 
6 Nissen SE, Tuzcu EM, Libby P, et al. CAMELOT Investigators. Effect of 
antihypertensive agents on cardiovascular events in patients with 
coronary disease and normal blood pressure: the CAMELOT study: a 
randomized controlled trial. JAMA 2004;292:2217-25. doi:10.1001/
jama.292.18.2217. 
7 Rouleau JL, Warnica WJ, Baillot R, et al. IMAGINE (Ischemia Management 
with Accupril post-bypass Graft via Inhibition of the coNverting Enzyme) 
Investigators. Effects of angiotensin-converting enzyme inhibition in 
low-risk patients early after coronary artery bypass surgery. Circulation 
2008;117:24-31. doi:10.1161/CIRCULATIONAHA.106.685073. 
8 Fihn SD, Gardin JM, Abrams J, et al. American College of Cardiology 
Foundation American Heart Association Task Force on Practice 
Guidelines American College of Physicians American Association for 
Thoracic Surgery Preventive Cardiovascular Nurses Association 
Society for Cardiovascular Angiography and Interventions Society of 
Thoracic Surgeons. 2012 ACCF/AHA/ACP/AATS/PCNA/SCAI/STS 
Guideline for the diagnosis and management of patients with stable 
ischemic heart disease: a report of the American College of Cardiology 
Foundation/American Heart Association Task Force on Practice 
Guidelines, and the American College of Physicians, American 
Association for Thoracic Surgery, Preventive Cardiovascular Nurses 
Association, Society for Cardiovascular Angiography and 
Interventions, and Society of Thoracic Surgeons. J Am Coll Cardiol 
2012;60:e44-164. doi:10.1016/j.jacc.2012.07.013. 
9 Higgins J, Green S. Cochrane Handbook for Systematic Reviews of 
Interventions Version 5.0.0 ed: Cochrane Collaboration, 2008. www.
cochrane-handbook.org.
10 Moher D, Cook DJ, Eastwood S, Olkin I, Rennie D, Stroup DF. Improving 
the quality of reports of meta-analyses of randomised controlled 
trials: the QUOROM statement. Quality of Reporting of Meta-analyses. 
Lancet 1999;354:1896-900. doi:10.1016/S0140-6736(99)04149-5. 
11 DerSimonian R, Laird N. Meta-analysis in clinical trials. Control Clin 
Trials 1986;7:177-88. doi:10.1016/0197-2456(86)90046-2. 
12 Sweeting MJ, Sutton AJ, Lambert PC. What to add to nothing? Use and 
avoidance of continuity corrections in meta-analysis of sparse data. 
Stat Med 2004;23:1351-75. doi:10.1002/sim.1761. 
13 Galbraith RF. A note on graphical presentation of estimated odds 
ratios from several clinical trials. Stat Med 1988;7:889-94. 
doi:10.1002/sim.4780070807. 
14 Dias S, Sutton AJ, Welton NJ, Ades AE. Evidence synthesis for decision 
making 3: heterogeneity—subgroups, meta-regression, bias, and 
bias-adjustment. Med Decis Making 2013;33:618-40. 
doi:10.1177/0272989X13485157. 
15 Arends LR, Hoes AW, Lubsen J, Grobbee DE, Stijnen T. Baseline risk as 
predictor of treatment benefit: three clinical meta-re-analyses. Stat Med 
2000;19:3497-518. doi:10.1002/1097-0258(20001230)19:24<3497: 
:AID-SIM830>3.0.CO;2-H. 
16 Higgins JP, Thompson SG. Controlling the risk of spurious findings from 
meta-regression. Stat Med 2004;23:1663-82. doi:10.1002/sim.1752. 
17 Bradburn MJ, Deeks JJ, Altman DG. Sbe24: metan—an alternative meta- 
analysis command. Stata Technical Bull Reprints 1998;8:86-100.
18 Thorlund K, Engstrøm J, Wetterslev J, Brok J, Imberger G, Gluud C. User 
manual for trial sequential analysis (TSA). 2011. www.ctu.dk/tsa.
19 Wetterslev J, Thorlund K, Brok J, Gluud C. Trial sequential analysis may 
establish when firm evidence is reached in cumulative meta-analysis. 
J Clin Epidemiol 2008;61:64-75. doi:10.1016/j.jclinepi.2007.03.013. 
20 Wetterslev J, Thorlund K, Brok J, Gluud C. Estimating required 
information size by quantifying diversity in random-effects model 
meta-analyses. BMC Med Res Methodol 2009;9:86. 
doi:10.1186/1471-2288-9-86. 
21 Elliott WJ, Meyer PM. Incident diabetes in clinical trials of 
antihypertensive drugs: a network meta-analysis. Lancet 
2007;369:201-7. doi:10.1016/S0140-6736(07)60108-1. 
22 Sorbets E, Labreuche J, Simon T, et al. Renin-angiotensin system 
antagonists and clinical outcomes in stable coronary artery disease 
without heart failure. Eur Heart J 2014;35:1760-8. doi:10.1093/
eurheartj/ehu078. 
Appendix: Supplementary material
